immunotherapy in second-line treatment of non-small cell lung cancer
Published 7 years ago • 261 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
3:02
neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer
-
1:19
developments in immunotherapy for lung cancer
-
2:33
lung cancer: post-frontline immunotherapy
-
1:26
progression is progression! the importance of monitoring the efficacy of immunotherapy in nsclc
-
3:43
immunotherapy for operable lung cancer
-
2:22
moving immunotherapy to earlier lines in nsclc
-
1:52
is adjuvant immunotherapy necessary in non-small cell lung cancer?
-
2:00
updated data from phase 2 study of alectinib in alk–positive non–small–cell lung cancer
-
2:59
chemotherapy in combination with immunotherapy for the treatment of metastatic thymic carcinoma
-
1:46
immunotherapy for lung cancer and trial of ramucirumab plus pembrolizumab
-
1:18
lung cancer: the impact of immunotherapy
-
1:12
updates in early stage non-small cell lung cancer
-
1:51
future directions for neoadjuvant immunotherapy in lung cancer
-
3:08
choosing immunotherapy as front line therapy for non-actionable nsclc
-
0:41
unmet needs in kras-driven non-small cell lung cancer
-
5:08
ultimate study: paclitaxel bevacizumab in non-squamous nsclc
-
1:54
balancing the benefits and costs of immunotherapy in the treatment of lung cancer
-
3:28
the future of nsclc treatment
-
2:54
considerations for duration and de-escalation of immunotherapy in lung cancer